EAM
RVNC
EULAV Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-500,000
| Closed | -$1.29M | – | 173 |
|
|
2024
Q2 | $1.29M | Hold |
500,000
| – | – | 0.03% | 166 |
|
|
2024
Q1 | $2.46M | Sell |
500,000
-130,000
| -21% | -$640K | 0.07% | 162 |
|
|
2023
Q4 | $5.54M | Buy |
630,000
+30,000
| +5% | +$264K | 0.17% | 120 |
|
|
2023
Q3 | $6.88M | Buy |
600,000
+440,000
| +275% | +$5.05M | 0.25% | 96 |
|
|
2023
Q2 | $4.05M | Buy |
160,000
+55,000
| +52% | +$1.39M | 0.15% | 132 |
|
|
2023
Q1 | $3.38M | Sell |
105,000
-65,000
| -38% | -$2.09M | 0.13% | 134 |
|
|
2022
Q4 | $3.14M | Buy |
+170,000
| New | +$3.14M | 0.13% | 138 |
|